Actively Recruiting
A Phase I Study of BRY812 Injection to Assess Safety and Effectiveness in Adults With Advanced Cancers
Led by BioRay Pharmaceutical Co., Ltd. · Updated on 2025-12-30
164
Participants Needed
1
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating BRY812 for injection in patients with advanced malignancies in this Phase I, multicenter, open-label, single-arm clinical study. The study aims to assess the safety, tolerability, how the drug moves through the body, its anti-tumor effects, and immune response in patients with advanced solid tumors who have not responded to or cannot tolerate standard treatments. This first-in-human trial is sponsored by BioRay Pharmaceutical Co., Ltd.
CONDITIONS
Brief Title
A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies
Research Team
H
He rui Yao, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here